Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
$1.83
+1.9%
$1.81
$1.29
$13.07
$108.90M-0.14683,092 shs343,689 shs
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
$6.37
$0.38
$1.24
$26.05M0.91522,308 shs466,373 shs
HilleVax, Inc. stock logo
HLVX
HilleVax
$2.06
-0.5%
$2.04
$1.34
$2.17
$103.29M0.77981,770 shs480,165 shs
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
$9.31
$10.17
$8.50
$23.00
$58.21MN/A37,647 shs794 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
0.00%+5.78%0.00%+23.65%-75.95%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00%0.00%0.00%0.00%0.00%
HilleVax, Inc. stock logo
HLVX
HilleVax
0.00%-0.96%-4.19%+10.75%+6.19%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00%-4.02%-6.43%-37.52%+930,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.6483 of 5 stars
4.63.00.00.02.02.50.6
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
1.1417 of 5 stars
1.04.00.00.00.03.31.3
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
3.17
Buy$16.80818.03% Upside
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
0.00
N/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
2.00
Hold$2.00-2.91% Downside
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest CLBS, BMEA, HLVX, and IZTC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $7.00
8/8/2025
HilleVax, Inc. stock logo
HLVX
HilleVax
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
8/6/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $10.00
8/6/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
8/5/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/21/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
7/16/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $9.00
6/24/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/13/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
6/3/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$7.00
6/2/2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/A$1.42 per shareN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/A$1.54 per shareN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/A$3.10 per shareN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/AN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$138.43M-$3.03N/AN/AN/AN/A-243.95%-140.74%11/4/2025 (Estimated)
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
-$27.47M-$0.41N/AN/AN/AN/A-27.24%-26.08%N/A
HilleVax, Inc. stock logo
HLVX
HilleVax
-$147.27M-$1.43N/AN/AN/AN/A-34.29%-28.50%11/6/2025 (Estimated)
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/A0.00N/AN/AN/AN/AN/A

Latest CLBS, BMEA, HLVX, and IZTC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
HilleVax, Inc. stock logo
HLVX
HilleVax
-$0.14-$0.11+$0.03-$0.11N/AN/A
8/5/2025Q2 2025
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
-$0.59-$0.51+$0.08-$0.51N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/AN/AN/AN/AN/A
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/AN/AN/AN/AN/A
HilleVax, Inc. stock logo
HLVX
HilleVax
N/AN/AN/AN/AN/A
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
N/A
3.68
3.68
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
N/A
22.33
22.33
HilleVax, Inc. stock logo
HLVX
HilleVax
N/A
26.39
26.39
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
96.72%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
15.57%
HilleVax, Inc. stock logo
HLVX
HilleVax
86.42%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A

Insider Ownership

CompanyInsider Ownership
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
18.42%
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2.20%
HilleVax, Inc. stock logo
HLVX
HilleVax
24.90%
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
5059.51 million48.55 millionOptionable
Caladrius Biosciences, Inc. stock logo
CLBS
Caladrius Biosciences
2760.58 million59.25 millionOptionable
HilleVax, Inc. stock logo
HLVX
HilleVax
2050.14 million37.66 millionNot Optionable
Invizyne Technologies Inc. stock logo
IZTC
Invizyne Technologies
296.25 millionN/AN/A

New MarketBeat Followers Over Time

Media Sentiment Over Time

Biomea Fusion stock logo

Biomea Fusion NASDAQ:BMEA

$1.83 +0.04 (+1.95%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$1.84 +0.01 (+0.55%)
As of 07:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Caladrius Biosciences stock logo

Caladrius Biosciences NASDAQ:CLBS

Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

HilleVax stock logo

HilleVax NASDAQ:HLVX

$2.06 -0.01 (-0.48%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$2.06 +0.00 (+0.24%)
As of 07:07 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Invizyne Technologies stock logo

Invizyne Technologies NASDAQ:IZTC

$9.31 0.00 (0.00%)
As of 08/22/2025

Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.